Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?
作者信息
Nielsen Travis B, Brass Eric P, Gilbert David N, Bartlett John G, Spellberg Brad
机构信息
From the Stritch School of Medicine and the Parkinson School of Health Sciences and Public Health, Loyola University Chicago, Maywood, IL (T.B.N.); the David Geffen School of Medicine at the University of California, Los Angeles (E.P.B.) and the Los Angeles County and University of Southern California Medical Center (B.S.) - both in Los Angeles; the Providence Portland Medical Center and University of Oregon Health Sciences School of Medicine, Portland (D.N.G.); and the Johns Hopkins University School of Medicine, Baltimore (J.G.B.).
出版信息
N Engl J Med. 2019 Aug 8;381(6):503-505. doi: 10.1056/NEJMp1905589. Epub 2019 Jun 19.
Abstract
摘要
相似文献
1
Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?抗生素的可持续发现与开发——非营利性方法会是未来的方向吗？
N Engl J Med. 2019 Aug 8;381(6):503-505. doi: 10.1056/NEJMp1905589. Epub 2019 Jun 19.
2
A three-step plan for antibiotics.抗生素使用的三步计划。
Nature. 2014 May 29;509(7502):533. doi: 10.1038/509533a.
3
Antibiotics at the crossroads.抗生素处于十字路口。
Nature. 2004 Oct 21;431(7011):899-902. doi: 10.1038/431899a.
4
Antibiotics--an investment worth making?
Nat Biotechnol. 2006 Dec;24(12):1512-4. doi: 10.1038/nbt1206-1512.
5
The antibacterial drugs market.抗菌药物市场。
Nat Rev Drug Discov. 2007 Jan;6(1):19-20. doi: 10.1038/nrd2226.
6
Busting the billion-dollar myth: how to slash the cost of drug development.打破十亿美元神话：如何大幅削减药物研发成本。
Nature. 2016 Aug 25;536(7617):388-90. doi: 10.1038/536388a.
7
The antibiotic paradox: why companies can't afford to create life-saving drugs.抗生素悖论：为何企业无力研发救命药物。
Nature. 2020 Aug;584(7821):338-341. doi: 10.1038/d41586-020-02418-x.
8
The urgent need for new antibacterial agents.对新型抗菌剂的迫切需求。
J Antimicrob Chemother. 2011 Sep;66(9):1939-40. doi: 10.1093/jac/dkr261. Epub 2011 Jun 23.
9
Repairing the broken market for antibiotic innovation.修复抗生素创新的失灵市场。
Health Aff (Millwood). 2015 Feb;34(2):277-85. doi: 10.1377/hlthaff.2014.1003.
10
Antibiotics: the changing regulatory and pharmaceutical industry paradigm.抗生素：不断变化的监管与制药行业范式
J Antimicrob Chemother. 2015 May;70(5):1281-4. doi: 10.1093/jac/dku572. Epub 2015 Jan 28.
引用本文的文献
1
Reserve antibiotics: overcoming limitations of evidence generated from regulatory approval trials.储备抗生素：克服监管批准试验所产生证据的局限性
Global Health. 2025 Apr 3;21(1):17. doi: 10.1186/s12992-025-01109-4.
2
Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR.利用IDentif.AI-AMR对鲍曼不动杆菌药物组合进行快速优化
NPJ Antimicrob Resist. 2025 Feb 21;3(1):12. doi: 10.1038/s44259-025-00079-2.
3
Sustainable solutions to the continuous threat of antimicrobial resistance.应对抗菌素耐药性持续威胁的可持续解决方案。
Health Aff Sch. 2025 Jan 24;3(2):qxaf012. doi: 10.1093/haschl/qxaf012. eCollection 2025 Feb.
4
Adjuvant strategies to tackle -mediated polymyxin resistance.应对多粘菌素耐药性的辅助策略。
RSC Med Chem. 2024 Nov 1. doi: 10.1039/d4md00654b.
5
Coalescence of co-infection and antimicrobial resistance with SARS-CoV-2 infection: The blues of post-COVID-19 world.合并感染与抗微生物药物耐药性与严重急性呼吸综合征冠状病毒2感染：新冠疫情后世界的困境。
Case Stud Chem Environ Eng. 2021 Jun;3:100093. doi: 10.1016/j.cscee.2021.100093. Epub 2021 Feb 21.
6
Pull me - push you? The disparate financing mechanisms of drug research in global health.拉我一把——推你一下？全球卫生领域药物研究的不同融资机制
Global Health. 2024 Feb 19;20(1):14. doi: 10.1186/s12992-024-01019-x.
7
Investigating the composition and recruitment of the mycobacterial ImuA'-ImuB-DnaE2 mutasome.研究分枝杆菌 ImuA'-ImuB-DnaE2 突变体的组成和募集。
Elife. 2023 Aug 2;12:e75628. doi: 10.7554/eLife.75628.
8
Metallacage-based enhanced PDT strategy for bacterial elimination via inhibiting endogenous NO production.基于金属笼的增强型 PDT 策略通过抑制内源性 NO 产生来消除细菌。
Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2218973120. doi: 10.1073/pnas.2218973120. Epub 2023 Jul 10.
9
Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group.肺炎研究中的未满足需求：CAPNETZ 研究小组的综合方法。
Respir Res. 2022 Sep 10;23(1):239. doi: 10.1186/s12931-022-02117-3.
10
Wars and sweets: microbes, medicines and other moderns in and beyond the(ir) antibiotic era.战争与糖果：抗生素时代及之后的微生物、药物与其他现代事物
Med Humanit. 2022 Aug 10;48(3):359-70. doi: 10.1136/medhum-2021-012366.
本文引用的文献
1
The future of antibiotics and resistance.抗生素与耐药性的未来。
N Engl J Med. 2013 Jan 24;368(4):299-302. doi: 10.1056/NEJMp1215093.
2
Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world.不再矛盾：非营利性制药公司为发展中世界提供药品承诺的潜力。
Health Aff (Millwood). 2005 Jul-Aug;24(4):1057-63. doi: 10.1377/hlthaff.24.4.1057.
Zotero 插件